To evaluate whether these results could be confirmed in a broader cohort of NOTCH1- or FBXW7-mutated T-ALL patients, we set up a drug treatment trial with nine different PDX samples. This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.